Eunice Wang, MD, Roswell Park Comprehensive Cancer Center

Articles

The Potential Future Impact of CAR T Cell Therapy in Adult ALL

July 7th 2021

Experts in hematology oncology consider unmet needs for adult patients with relapsed/refractory ALL and reflect on the potential impact that FDA approval of CAR T cell therapy would have on the treatment landscape.

The ZUMA-3 Trial: Clinical Endpoints

July 7th 2021

Thought leaders in the management of ALL discuss the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy, and lead trial author Bijal Shah, MD, MS, comments on the future application of MRD status.

The ZUMA-3 Trial: Efficacy and Safety Results

July 7th 2021

Primary investigator Bijal Shah, MD, MS, shares insights into the efficacy results of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy for acute lymphocytic leukemia (ALL), and Eunice Wang, MD, reviews the trial’s key safety data.

The ZUMA-3 Trial: Study Design and Patient Population

July 7th 2021

Leukemia experts provide an overview of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy in adult patients with relapsed/refractory acute lymphocytic leukemia (ALL) by discussing the overall study design and patient population.

Using MRD to Monitor Therapeutic Response in  ALL 

June 30th 2021

Key experts in hematology oncology discuss the use of MRD status to assess therapeutic response and guide treatment decisions in patients with relapsed/refractory ALL.  

The Evolving Treatment Landscape for ALL 

June 30th 2021

Eunice Wang, MD and Bijal Shah, MD, MS, begin with an overview of novel agents and emerging therapeutic approaches for the treatment of acute lymphoblastic leukemia.  

Future Treatment Landscape of AML

March 15th 2021

Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.

Maintenance Therapy Post-Transplant in AML

March 15th 2021

Patient selection for maintenance therapy post-allogeneic transplant in myeloid malignancies and thoughts on treatment of FLT3-mutated disease post-transplant with agents such as midostaurin.

Use of APR-246 and Oral HMAs in AML

March 8th 2021

Role of Transplant in AML

March 8th 2021

Use of Omidubicel Therapy in Hematologic Malignancies

March 1st 2021

BMT CTN 1102 Study in High-Risk MDS

March 1st 2021

Novel Targets and Biomarkers in AML

February 22nd 2021

IDH1/2-Mutated Treatment-Naïve AML

February 22nd 2021

BCL2 Inhibition in AML: VIALE-A Study

February 15th 2021

Type 1/2 FLT3 Inhibitors in AML

February 15th 2021

Role of Dual Targeted Therapy in AML

February 8th 2021

Sequencing of FLT3 Inhibitors in AML

February 8th 2021

Management of AML: FLT3 Inhibitors and BCL2 Inhibitors

February 1st 2021

Role of FLT3 Inhibitors in Chemo-Ineligible AML

February 1st 2021